The importance of grasslands for animal production and other functions: a review on management and methodological progress in the tropics

The global importance of grasslands is indicated by their extent; they comprise some 26% of total land area and 80% of agriculturally productive land. The majority of grasslands are located in tropical developing countries where they are particularly important to the livelihoods of some one billion poor peoples. Grasslands clearly provide the feed base for grazing livestock and thus numerous high-quality foods, but such livestock also provide products such as fertilizer, transport, traction, fibre and leather. In addition, grasslands provide important services and roles including as water catchments, biodiversity reserves, for cultural and recreational needs, and potentially a carbon sink to alleviate greenhouse gas emissions. Inevitably, such functions may conflict with management for production of livestock products. Much of the increasing global demand for meat and milk, particularly from developing countries, will have to be supplied from grassland ecosystems, and this will provide difficult challenges. Increased production of meat and milk generally requires increased intake of metabolizable energy, and thus increased voluntary intake and/or digestibility of diets selected by grazing animals. These will require more widespread and effective application of improved management. Strategies to improve productivity include fertilizer application, grazing management, greater use of crop by-products, legumes and supplements and manipulation of stocking rate and herbage allowance. However, it is often difficult to predict the efficiency and cost-effectiveness of such strategies, particularly in tropical developing country production systems. Evaluation and on-going adjustment of grazing systems require appropriate and reliable assessment criteria, but these are often lacking. A number of emerging technologies may contribute to timely low-cost acquisition of quantitative information to better understand the soil-pasture-animal interactions and animal management in grassland systems. Development of remote imaging of vegetation, global positioning technology, improved diet markers, near IR spectroscopy and modelling provide improved tools for knowledge-based decisions on the productivity constraints of grazing animals. Individual electronic identification of animals offers opportunities for precision management on an individual animal basis for improved productivity. Improved outcomes in the form of livestock products, services and/or other outcomes from grasslands should be possible, but clearly a diversity of solutions are needed for the vast range of environments and social circumstances of global grasslands.     

Aspects of the political economy of development and synthetic biology

What implications might synthetic biology’s potential as a wholly new method of production have for the world economy, particularly developing countries? Theories of political economy predict that synthetic biology can shift terms of trade and displace producers in developing countries. Governments, however, retain the ability to mitigate negative changes through social safety nets and to foster adaptation to some changes through research, education and investment. We consider the effects the synthetic production of otherwise naturally derived molecules are likely to have on trade and investment, particularly in developing countries. Both rubber in Malaysia and indigo dyes in India provide historical examples of natural molecules that faced market dislocations from synthetic competitors. Natural rubber was able to maintain significant market share, while natural indigo vanished from world markets. These cases demonstrate the two extremes of the impact synthetic biology might have on naturally derived products. If developing countries can cushion the pain of technological changes by providing producers support as they retool or exit, the harmful effects of synthetic biology can be mitigated while its benefits can still be captured.     

Progress in the Standardization of Stains Certain Less Commonly Used Stains

The Commission must acknowledge the assistance recently given by two commercial concerns in developing two new products, namely, a pure type of hematein and a special grade of acid fuchsin.     

Progress in the Standardization of Stains

The Commission must acknowledge the assistance recently given by two commercial concerns in developing two new products, namely, a pure type of hematein and a special grade of acid fuchsin.     

China's perspective on similar biotherapeutic products

In order to ensure most Chinese patients, particularly in the population with relatively low incomes, have access to safe, low cost, effective and quality-assured medicines, a number of "stand-alone" biological products, which have good quality, safety and efficacy have been marketed in China. Many countries and regions' regulatory agencies are actively engaging in the development of bio-similar guidance and documents, which is being coordinated by WHO. As a major developing country of new drug development, China is now working hard to promote the process of new similar biotherapeutic products (SBPs) approval and also actively involved in developing and updating technical documents.     

Liposomal Hepatitis A Vaccine and Liposomal Multiantigen Combination Vaccines

Abstract

Many antigens are only weak immunogens, and they require adjuvants to reach a satisfactory immune response as vaccines. This is especially true for modern antigens, such as products of gene technology or synthetic peptides. Also, classically produced antigens such as diphtheria or tetanus-antigens are coupled on aluminium phosphate or aluminium hydroxide – to this day practically the only adjuvant class which is routinely used in vaccinology. Aluminium phosphate was first used in the 1920s as an immunopotentiator for the diphtheria vaccine. Since then, and up until now, it has not been possible to fully replace this unsatisfactory adjuvant. exclusion of epitope-specific suppression by the individual components, it was evident that particularly the diphtheria and tetanus constituents exerted “antigenic competition” on the HAV antigen and possibly also on the HBs antigen. By reducing the diphtheria and tetanus toxoid subunit molecules per IRIV particle, it was possible not only to increase significantly the immune response to these antigens but also to remove completely the antigenic competition on the HAV and HBs antigens. Once the optimum composition of the vaccine had been achieved (careful dosing of antigens per IRIV particle), an immunological effect clearly superior to that of comparable, aluminium-adsorbed products was obtained (Table II). The tolerability of this “supercombi vaccine” was significantly better than the commercial alum adsorbed products (Table III).     

Current Risk Assessment Approaches to Address Petroleum Hydrocarbon Mixtures in Soils

Products that exist as complex chemical mixtures, such as petroleum products, are used widely in commerce, and accidental releases of these products into the environment have led to thousands of contaminated sites nationwide. Developing sound estimates of potential health risks posed by these sites is challenging because of the composition of these products, their behavior in the environment, and the paucity of toxicological information available for many of the component compounds. In developing risk based cleanup goals for petroleum products and other complex commercial mixtures, the simplest approach is to assume that the entire mixture is comprised of the most toxic constituent, particularly when standards are unavailable for each of the components of the mixture. This approach often results in excessively conservative regulatory goals; thus, methods are needed which more accurately reflect the actual composition and aggregate toxicity of the mixture. Three approaches for the development of risk based soil cleanup goals for petroleum hydrocarbon mixtures are identified and illustrated using mineral spirits as an example. For the examples presented, estimates of the proportions of components in mineral spirits were based on virgin, unused product; however, detailed component analysis of weathered samples may permit the calculation of more precise, site specific cleanup goals.     

Faox enzymes inhibited Maillard reaction development during storage both in protein glucose model system and low lactose UHT milk

Fructosamines, also known as Amadori products, are formed by the condensation of glucose with the amino group of amino acids or proteins. These compounds are precursors of advanced glycation end products (AGEs) that can be formed either endogenously during aging and diabetes, and exogenously in heat-processed food. The negative effects of dietary AGEs on human health as well as their negative impact on the quality of dairy products have been widely described, therefore specific tools able to prevent the formation of glycation products are needed. Two fructosamine oxidase enzymes isolated from Aspergillus sp. namely, Faox I and Faox II catalyze the oxidative deglycation of Amadori products representing a potential tool for inhibiting the Maillard reaction in dairy products. In this paper, the ability of recombinant Faox I and II in limiting the formation of carboxy-methyl lysine (CML) and protein-bound hydroxymethyl furfurol (b-HMF) in a commercial UHT low lactose milk and a beta-lactoglobulin (β-LG) glucose model system was investigated. Results show a consistent reduction of CML and b-HMF under all conditions. Faox effects were particularly evident on b-HMF formation in low lactose commercial milk. Peptide analysis of the β-LG glucose system identified some peptides, derived from cyanogen bromide hydrolysis, as suitable candidates to monitor Faox action in milk-based products. All in all data suggested that non-enzymatic reactions in dairy products might be strongly reduced by implementing Faox enzymes.     

Sowing the seeds of success: pharmaceutical proteins from plants

Among the many plant-based production systems that have been developed for pharmaceutical proteins, seeds have the useful advantage of accumulating proteins in a relatively small volume and in a stable environment in which they are protected from degradation. Several seed crops, including cereals, grain legumes and oilseeds, have been explored as production platforms, and the first commercial products -- all technical proteins and enzymes -- have already reached the market. Recent studies have explored the use of seeds for the production of pharmaceutical proteins, particularly replacement human proteins, recombinant antibodies and (oral) vaccines.     

Chemically defined media for commercial fermentations

The use of chemically defined media is gaining popularity in some commercial fermentations, particularly for the preparation of biological products. Although these media are still not frequently developed for industrial processes, they do exhibit favorable characteristics at large scale that are not observed with traditional complex media. This review focuses on the application, development, and practical considerations, especially process economics, of fermentations in chemically defined media in an industrial environment. Received: 3 August 1998 / Received revision: 16 November 1998 / Accepted: 21 November 1998     

Development of health biotechnology in developing countries: Can private-sector players be the prime movers?

Health biotechnology has rapidly become vital in helping healthcare systems meet the needs of the poor in developing countries. This key industry also generates revenue and creates employment opportunities in these countries. To successfully develop biotechnology industries in developing nations, it is critical to understand and improve the system of health innovation, as well as the role of each innovative sector and the linkages between the sectors. Countries' science and technology capacities can be strengthened only if there are non-linear linkages and strong interrelations among players throughout the innovation process; these relationships generate and transfer knowledge related to commercialization of the innovative health products. The private sector is one of the main actors in healthcare innovation, contributing significantly to the development of health biotechnology via knowledge, expertise, resources and relationships to translate basic research and development into new commercial products and innovative processes. The role of the private sector has been increasingly recognized and emphasized by governments, agencies and international organizations. Many partnerships between the public and private sector have been established to leverage the potential of the private sector to produce more affordable healthcare products. Several developing countries that have been actively involved in health biotechnology are becoming the main players in this industry. The aim of this paper is to discuss the role of the private sector in health biotechnology development and to study its impact on health and economic growth through case studies in South Korea, India and Brazil. The paper also discussed the approaches by which the private sector can improve the health and economic status of the poor.     

High Capacity Chemisorbents for Protein Immobilization

IMMOBILIZED proteins have been used successfully for the purification and isolation of specific natural products, particularly proteins such as antigens, antibodies, enzymes and enzyme inhibitors^1–3. They have also been used for the commercial production of biochemicals⁴ and as models for imitating enzymes bound to cellular components in vivo.     

Trends in the Discovery of New Marine Natural Products from Invertebrates over the Last Two Decades – Where and What Are We Bioprospecting?

It is acknowledged that marine invertebrates produce bioactive natural products that may be useful for developing new drugs. By exploring untapped geographical sources and/or novel groups of organisms one can maximize the search for new marine drugs to treat human diseases. The goal of this paper is to analyse the trends associated with the discovery of new marine natural products from invertebrates (NMNPI) over the last two decades. The analysis considers different taxonomical levels and geographical approaches of bioprospected species. Additionally, this research is also directed to provide new insights into less bioprospected taxa and world regions. In order to gather the information available on NMNPI, the yearly-published reviews of Marine Natural Products covering 1990-2009 were surveyed. Information on source organisms, specifically taxonomical information and collection sites, was assembled together with additional geographical information collected from the articles originally describing the new natural product. Almost 10000 NMNPI were discovered since 1990, with a pronounced increase between decades. Porifera and Cnidaria were the two dominant sources of NMNPI worldwide. The exception was polar regions where Echinodermata dominated. The majority of species that yielded the new natural products belong to only one class of each Porifera and Cnidaria phyla (Demospongiae and Anthozoa, respectively). Increased bioprospecting efforts were observed in the Pacific Ocean, particularly in Asian countries that are associated with the Japan Biodiversity Hotspot and the Kuroshio Current. Although results show comparably less NMNPI from polar regions, the number of new natural products per species is similar to that recorded for other regions. The present study provides information to future bioprospecting efforts addressing previously unexplored taxonomic groups and/or regions. We also highlight how marine invertebrates, which in some cases have no commercial value, may become highly valuable in the ongoing search for new drugs from the sea.     

Product Diversity and Spectrum of Choice in Hospital ePrescribing Systems in England

Background

ePrescribing systems have considerable potential for improving healthcare quality and safety. With growing expectations about the benefits of such systems, there is evidence of widespread plans to implement these systems in hospitals in England where hitherto they have had a low uptake. Given the international drive away from developing home-grown to systems to procuring commercial applications, we aimed to identify available ePrescribing systems in England and to use the findings to develop a taxonomy of the systems offered by suppliers.

Methods and Findings

We undertook a scoping review of the published and grey literature, and conducted expert interviews with vendors, healthcare organisations and national ePrescribing experts in order to identify the spectrum of available systems, identify and map their key features, and then iteratively develop and validate a taxonomy of commercial ePrescribing systems available to English hospitals. There is a wide range of available systems including 13 hospital-wide applications and a range of specialty systems. These commercial applications can be grouped into four sub-categories: standalone systems, modules within integrated systems, functionalities spread over several modules, and specialty systems. The findings also reveal that apart from four packaged applications (two of which are specialty systems), all other systems have none or less than two live implementations across England.

Conclusions

The wide range of products developed in the last few years by different national and international suppliers, and the low uptake of these products by English hospitals indicate that the English ePrescribing market is still in its infancy. This market is undergoing rapid cycles of change, both with respect to the number of suppliers and their diversity of offerings. Constant renewal of knowledge is needed on the status of this evolving market, encompassing the products development and adoption, to assist implementation decisions and facilitate market maturity.     

An application in cheddar cheese manufacture for a strain of Lactococcus lactis producing a novel broad-spectrum bacteriocin, lacticin 3147.

Lactococcus lactis DPC3147, a strain isolated from an Irish kefir grain, produces a bacteriocin with a broad spectrum of inhibition. The bacteriocin produced is heat stable, particularly at a low pH, and inhibits nisin-producing (Nip+) lactococci. On the basis of the observation that the nisin structural gene (nisA) does not hybridize to DPC3147 genomic DNA, the bacteriocin produced was considered novel and designated lacticin 3147. The genetic determinants which encode lacticin 3147 are contained on a 63-kb plasmid, which was conjugally mobilized to a commercial cheese starter, L. lactis subsp. cremoris DPC4268. The resultant transconjugant, DPC4275, both produces and is immune to lacticin 3147. The ability of lacticin 3147-producing lactococci to perform as cheddar cheese starters was subsequently investigated in cheesemaking trials. Bacteriocin-producing starters (which included the transconjugant strain DPC4275) produced acid at rates similar to those of commercial strains. The level of lacticin 3147 produced in cheese remained constant over 6 months of ripening and correlated with a significant reduction in the levels of nonstarter lactic acid bacteria. Such results suggest that these starters provide a means of controlling developing microflora in ripened fermented products.     

Microbial selection strategies that enhance the likelihood of developing commercial biological control products

Research interest in utilizing microorganisms to create a microbial environment suppressive to plant pathogens has increased exponentially in recent years. Despite intense interest in developing biological control agents, relatively few antagonists have achieved ‘commercial product’ status. The fact that such a small proportion of active laboratory antagonists are developed into biological control products is partly due to several features common to microbial selection strategies that are widely utilized to obtain putative biological control agents: (a) relatively few candidate microorganisms are tested; (b) microbes are selected based on the results of an assay that does not replicate field conditions; and (c) the amenability of microbes to commercial development is excluded as a selection criterion. Selection strategies that enhance the likelihood of developing commercial biological control products are described. These include making appropriate choices regarding the pathosystem for biological control, the method of microbe isolation, and the method of isolate characterization and performance evaluation. A model system of developing a biological control product active against Gibberella pulicaris (Fries) Sacc. (anamorph: Fusarium sambucinum Fuckel), the primary causal agent of Fusarium dry rot of stored potatoes, is used to illustrate the proposed selection strategy concepts. The crucial importance and methodology is described, of selecting strains with enhanced potential for commercial development based on a strain exhibiting both favorable growth kinetics and bioefficacy when grown in commercially feasible liquid media. Received 06 February 1997/ Accepted in revised form 29 May 1997     

Global capture of crop biotechnology in developing world over a decade

There is an urgent need for the advancement of agricultural technology (e.g. crop biotechnology or genetic modification (GM) technology), particularly, to address food security problem, to fight against hunger and poverty crisis and to ensure sustainable agricultural production in developing countries. Over the past decade, the adoption of GM technology on a commercial basis has increased steadily around the world with a significant impact in terms of socio-economic, environment and human health benefits. However, GM technology is still surrounded by controversial debates with several factors hindering the adoption of GM crops. This paper reviews current literatures on commercial production of GM crops, and assesses the benefits and constraints associated with adoption of GM crops in developing countries in the last 15 years. This article provides policy implication towards advancing the development and adoption of GM technology in developing countries and concludes with summary of key points discussed.     

Best practices for companion diagnostic and therapeutic development: translating between the stakeholders

By 2012 the pharmaceutical industry has generally recognized the value proposition offered through 'personalized medicine': shorter regulatory reviews and higher prices as a tradeoff for a more specific patient market. Examples of companion diagnostics (Cdx) exist not only in oncology, but across therapeutic areas that allow us to define treatment benefit and identify the 'best patients' for a given treatment approach or combination thereof. In the 13 years since the co-approval of trastuzumab (Herceptin(?)) from Genentech and the HercepTest(?) from Dako, the regulatory and commercial environments have yet to adopt a standard methodology for co-development and co-approval. Furthermore, a one-size-fits-all approach is unlikely to emerge despite attempts by various stakeholders to create an environment of conformity for approval and reimbursement issues. What has emerged, however, is the experience of clinical developers and commercial teams in bringing these products to market. In this article, we focus on the many factors that should be considered to successfully develop and market a companion diagnostic, based on lessons learned from recent case studies. A proposed framework of questions to be addressed at the various stages of developing highly effective companion diagnostic products is also presented.     

Valuation and sustainable use of tropical rainforest

Studies of the extraction of non-timber forest products have shown that the standing rainforest may be more valuable than alternatives involving deforestation

Although this article is about placing a value on rainforest, it begins by stressing the importance and value of rainforest for its environmental function, particularly for the control of world climate patterns. It is then shown how rainforest peoples depend on the plants around them and in some study areas were found to have a use for every tree on the one-hectare plots. It is therefore not surprising that the rainforest can contain many non-timber forest products (NTFPs) of commercial potential, some of which such as rubber latex and Brazil nuts have been in the market economy for many years. A summary is given of various attempts to place a value on rainforest for its NTFPs. Each of the three studies showed that the extraction of these products could be more valuable than alternative land uses involving deforestation. Various rainforest countries such as Brazil, Guatemala, and Indonesia have set up extractive reserves where local people are allowed to extract NTFPs but not to clear cut the forest. Extractive reserves have slowed down deforestation in some areas, but only provide a meagre subsistence existence for their inhabitants, so while they are useful, they are not a panacea that will solve all the conservation problems of tropical rainforest.     

Automated polymerase chain reaction product sample preparation for capillary electrophoresis analysis

The analysis of crude polymerase chain reaction (PCR) products by capillary electrophoresis (CE) is often compromised due to the presence of a high concentration of salt. Salt interferes with the electrokinetic injection and induces localized heating within the column; hence, PCR products must be desalted or cleaned-up prior to CE analysis. A variety of commercial clean-up systems are available that have been traditionally used to prepare PCR products for cloning, sequencing and digestion with restriction enzymes. These systems were tested for their effectiveness in preparing PCR products for CE analysis and were evaluated based on CE resolution, salt removal, DNA recovery, processing time and cost. One particularly effective clean-up system, membrane dialysis, was automated using a robotic workstation.